Copenhagen, 2015-12-17 09:12 CET (GLOBE NEWSWIRE) -- Exiqon A/S, listed on Nasdaq Copenhagen (‘EXQ’), today announced that the recently issued senior secured notes in the amount of DKK 40 million (‘Note’) will be admitted to trading at First North Bond Market effective as of 18 December 2015. The terms and conditions pertaining to the Note and a company description are enclosed and may be found at: http://www.exiqon.com/investor/FirstNorthBondMarketIssue
Additional information
Lars Kongsbak, CEO, mobile phone: +45 4090 2101
Hans Henrik Chrois Christensen, CFO, mobile phone: +45 4090 2131
About Exiqon
Exiqon operates in two business areas: Exiqon Life Sciences, a leading provider of flexible solutions for RNA analysis. Exiqon’s research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases, which can help physicians make treatment decisions based on the tools developed by Exiqon Life Sciences. Exiqon is listed on NASDAQ in Copenhagen. For more information about us, please visit www.exiqon.com
